CD8A and neoplasm: While this regimen resulted in systemic and intratumoral immune activation with a Th1 and type 1 IFN gene expression signatures, intratumoral CD8+ T cell infiltration and tumor PD-L1 expression, none of the 52 included patients showed an objective response to treatment.